Cargando…

Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours—A Single Centre Cohort

SIMPLE SUMMARY: Neuroendocrine tumours of the upper part of the small intestine are rare. They are slow growing but may spread to lymph nodes or other organs already when the tumours are small. Such tumours may be treated by endoscopic removal or by an operation. In the current study we present the...

Descripción completa

Detalles Bibliográficos
Autores principales: Folkestad, Oddry, Wasmuth, Hans H., Mjønes, Patricia, Fougner, Reidun, Hauso, Øyvind, Fossmark, Reidar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391208/
https://www.ncbi.nlm.nih.gov/pubmed/34439140
http://dx.doi.org/10.3390/cancers13163985
_version_ 1783743220793999360
author Folkestad, Oddry
Wasmuth, Hans H.
Mjønes, Patricia
Fougner, Reidun
Hauso, Øyvind
Fossmark, Reidar
author_facet Folkestad, Oddry
Wasmuth, Hans H.
Mjønes, Patricia
Fougner, Reidun
Hauso, Øyvind
Fossmark, Reidar
author_sort Folkestad, Oddry
collection PubMed
description SIMPLE SUMMARY: Neuroendocrine tumours of the upper part of the small intestine are rare. They are slow growing but may spread to lymph nodes or other organs already when the tumours are small. Such tumours may be treated by endoscopic removal or by an operation. In the current study we present the treatment results of 32 patients with this rare tumour. We found that the long-term survival was long, and patients more often died from other diseases. The survival was associated with the growth rate of the tumours and whether all the tumour tissue could be removed. Endoscopic removal was sufficient for smaller tumours <10 mm, whereas a high proportion of tumours 10–20 mm have lymph node metastases that must be removed by an operation to make patients tumour free. None of the tumours that were perceived as cured after removal recurred after an average follow-up time of 4.8 years. ABSTRACT: Background: Duodenal neuroendocrine tumours (D-NETs) are rare but increasingly diagnosed. This study aimed to assess the overall survival and recurrence rate among patients treated for D-NETs. Methods: Patients with D-NETs were retrospectively reviewed with a median follow-up time of 4.8 years (range 0.0–17.2 years). Results: A total of 32 patients with median age 68.0 years were identified. Fifteen patients underwent surgery while ten patients underwent endoscopic treatment. Mean estimated overall survival for the entire population was 12.1 years (95% CI 9.5–14.7 years), while 5-year overall survival was 81.3%. Tumour grade G1 was associated with longer mean estimated survival compared to G2 tumours (13.2 years versus 4.4 years, p = 0.010). None of the 23 patients who underwent presumed radical endoscopic or surgical resection had disease recurrence during follow-up. Tumours <10 mm could be treated endoscopically whereas a high proportion of patients with tumours 10–20 mm should be considered for surgery. Conclusion: Patients with D-NETs had long overall survival, and mortality was more influenced by other diseases. Both endoscopic and surgical resections were effective as no recurrences were diagnosed during follow-up.
format Online
Article
Text
id pubmed-8391208
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83912082021-08-28 Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours—A Single Centre Cohort Folkestad, Oddry Wasmuth, Hans H. Mjønes, Patricia Fougner, Reidun Hauso, Øyvind Fossmark, Reidar Cancers (Basel) Article SIMPLE SUMMARY: Neuroendocrine tumours of the upper part of the small intestine are rare. They are slow growing but may spread to lymph nodes or other organs already when the tumours are small. Such tumours may be treated by endoscopic removal or by an operation. In the current study we present the treatment results of 32 patients with this rare tumour. We found that the long-term survival was long, and patients more often died from other diseases. The survival was associated with the growth rate of the tumours and whether all the tumour tissue could be removed. Endoscopic removal was sufficient for smaller tumours <10 mm, whereas a high proportion of tumours 10–20 mm have lymph node metastases that must be removed by an operation to make patients tumour free. None of the tumours that were perceived as cured after removal recurred after an average follow-up time of 4.8 years. ABSTRACT: Background: Duodenal neuroendocrine tumours (D-NETs) are rare but increasingly diagnosed. This study aimed to assess the overall survival and recurrence rate among patients treated for D-NETs. Methods: Patients with D-NETs were retrospectively reviewed with a median follow-up time of 4.8 years (range 0.0–17.2 years). Results: A total of 32 patients with median age 68.0 years were identified. Fifteen patients underwent surgery while ten patients underwent endoscopic treatment. Mean estimated overall survival for the entire population was 12.1 years (95% CI 9.5–14.7 years), while 5-year overall survival was 81.3%. Tumour grade G1 was associated with longer mean estimated survival compared to G2 tumours (13.2 years versus 4.4 years, p = 0.010). None of the 23 patients who underwent presumed radical endoscopic or surgical resection had disease recurrence during follow-up. Tumours <10 mm could be treated endoscopically whereas a high proportion of patients with tumours 10–20 mm should be considered for surgery. Conclusion: Patients with D-NETs had long overall survival, and mortality was more influenced by other diseases. Both endoscopic and surgical resections were effective as no recurrences were diagnosed during follow-up. MDPI 2021-08-06 /pmc/articles/PMC8391208/ /pubmed/34439140 http://dx.doi.org/10.3390/cancers13163985 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Folkestad, Oddry
Wasmuth, Hans H.
Mjønes, Patricia
Fougner, Reidun
Hauso, Øyvind
Fossmark, Reidar
Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours—A Single Centre Cohort
title Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours—A Single Centre Cohort
title_full Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours—A Single Centre Cohort
title_fullStr Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours—A Single Centre Cohort
title_full_unstemmed Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours—A Single Centre Cohort
title_short Survival and Disease Recurrence in Patients with Duodenal Neuroendocrine Tumours—A Single Centre Cohort
title_sort survival and disease recurrence in patients with duodenal neuroendocrine tumours—a single centre cohort
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391208/
https://www.ncbi.nlm.nih.gov/pubmed/34439140
http://dx.doi.org/10.3390/cancers13163985
work_keys_str_mv AT folkestadoddry survivalanddiseaserecurrenceinpatientswithduodenalneuroendocrinetumoursasinglecentrecohort
AT wasmuthhansh survivalanddiseaserecurrenceinpatientswithduodenalneuroendocrinetumoursasinglecentrecohort
AT mjønespatricia survivalanddiseaserecurrenceinpatientswithduodenalneuroendocrinetumoursasinglecentrecohort
AT fougnerreidun survivalanddiseaserecurrenceinpatientswithduodenalneuroendocrinetumoursasinglecentrecohort
AT hausoøyvind survivalanddiseaserecurrenceinpatientswithduodenalneuroendocrinetumoursasinglecentrecohort
AT fossmarkreidar survivalanddiseaserecurrenceinpatientswithduodenalneuroendocrinetumoursasinglecentrecohort